

A Study to Further Understand the Effects of SCH 527123 on Tissue Neutrophils

ACTRN12609000661279

Status	RECRUITING
Sponsor	Schering-Plough
Enrollment	23 participants

Plain Language Summary

This study is testing a drug called SCH 527123, which may help control inflammation by reducing the number of white blood cells called neutrophils in tissues. Too many neutrophils in tissues can cause or worsen inflammatory conditions like COPD. This trial has two parts: Part 1 tests whether a 100 mg dose is safe in healthy adults over 14 days. Part 2 looks at how different doses of SCH 527123 compare to placebo (inactive pill) and prednisone (a steroid) in reducing neutrophils in the mouth lining. The results may help guide future studies in people with COPD.

You may be eligible if:

- You are between 18 and 65 years old
- You are a healthy adult
- You are free of moderate or severe mouth disease (for Part 2)

You may NOT be eligible if:

- You have a history of cancer
- You currently smoke
- You have HIV, Hepatitis B, or Hepatitis C
- Your neutrophil count is low (below $2.5 \times 10^9/L$)

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (2)

- Part 1: Healthy adult
- Part 2: Healthy adult, free of moderate or severe oral mucosal disease

Exclusion (1)

- History of malignancy, subjects who smoke, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, Neutrophil count of $< 2.5 \times 10^9/L$

Locations (1 total)

Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12609000661279>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.